(Total Views: 478)
Posted On: 03/07/2021 5:24:40 PM
Post# of 155731
I disagree. I think both populations were valuable. It's not like we were turning down critical patients from the trial, there just weren't as many of them. It would have taken much longer and more sites and more money to get more critical patients.
They probably should have stratified by age though, randomzing equally the over and under 65s so we wouldn't get 33% over 65 in LL arm vs. 22% in placebo.
Would have been nice if background standard of care was standardized too but have to be practical.
Most impressive result to me that in 309 total who receive standard treatment, we actually met our 28 day mortality endpoint with p=0.03.
They probably should have stratified by age though, randomzing equally the over and under 65s so we wouldn't get 33% over 65 in LL arm vs. 22% in placebo.
Would have been nice if background standard of care was standardized too but have to be practical.
Most impressive result to me that in 309 total who receive standard treatment, we actually met our 28 day mortality endpoint with p=0.03.
(3)
(0)
